製薬

Elix Provides AI Drug Discovery Platform “Elix DiscoveryTM” to KYORIN Pharmaceutical

Elix, Inc., a Japan-based AI drug discovery company, is pleased to announce that KYORIN Pharmaceutical Co., Ltd. has adopted Elix DiscoveryTM, Elix’s proprietary AI-powered drug discovery platform. In traditional drug development, researchers face the challenge of identifying promising compounds from vast chemical libraries, which often results in prolonged research timelines, escalating R&D costs, and low success rates. Against this backdrop, AI technologies are increasingly recognized for their potential to streamline the drug discovery process and improve success probabilities. In particular, AI-driven molecular design and compound profiling can enable the efficient generation of promising compounds, accelerating the selection, synthesis, and evaluation processes. Elix is a pioneering Japan-based AI drug discovery company on a mission to "Rethink Drug Discovery," partnering with pharmaceutical companies, universities, research institutions, and biotech startups. Its flagship platform,…